Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

298
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
298
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

633
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
633

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relacorilant: First Approval.

Drugs·2026
Same author

Rovadicitinib: First Approval.

Drugs·2026
Same author

Sonrotoclax: First Approval.

Drugs·2026
Same author

Copper Histidinate: Pediatric First Approval.

Paediatric drugs·2026
Same author

Correction: Avutometinib and Defactinib: First Approval.

Drugs·2026
Same author

Lerodalcibep: First Approval.

Drugs·2026

Related Experiment Video

Updated: Feb 22, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

GP2013: A Rituximab Biosimilar.

Hannah A Blair1

  • 1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|September 19, 2017
PubMed
Summary

GP2013, a biosimilar of rituximab, is approved in the EU for multiple cancers and autoimmune diseases. Clinical studies show GP2013 has equivalent efficacy and similar safety to rituximab, offering a viable alternative.

Area of Science:

  • Oncology
  • Immunology
  • Rheumatology

Background:

  • Rituximab, a monoclonal anti-CD20 antibody, is a well-established therapy for various cancers and autoimmune conditions.
  • The development of biosimilars offers potential for increased access to effective treatments.

Purpose of the Study:

  • To evaluate the efficacy, safety, tolerability, and immunogenicity of GP2013, a biosimilar of rituximab.
  • To confirm biosimilarity of GP2013 to reference rituximab across multiple indications.

Main Methods:

  • Comparative physicochemical and pharmacodynamic assessments.
  • Pharmacokinetic studies in rheumatoid arthritis patients.
  • Clinical efficacy and safety evaluation in follicular lymphoma patients.

More Related Videos

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

1.2K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.4K

Related Experiment Videos

Last Updated: Feb 22, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

1.2K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.4K

Main Results:

  • GP2013 demonstrated physicochemical and pharmacodynamic similarity to reference rituximab.
  • Pharmacokinetic biosimilarity was established in patients with rheumatoid arthritis.
  • GP2013 showed equivalent clinical efficacy and a comparable safety profile to rituximab in follicular lymphoma.

Conclusions:

  • GP2013 is an effective biosimilar alternative to rituximab for approved indications.
  • The tolerability, immunogenicity, and safety profiles of GP2013 are similar to reference rituximab.
  • GP2013 provides a valuable treatment option for patients requiring rituximab therapy.